Articles tagged with Parkinsons Disease
A new study found that disease-modifying antirheumatic drugs do not protect people with rheumatoid arthritis from developing Parkinson's disease. However, using chloroquine or hydroxychloroquine was associated with a lower risk of PD. The study controlled for various factors, including comorbidities and age.
Researchers found that CBN preserves mitochondrial function and prevents oxidative damage to nerve cells, suggesting potential for treating age-related neurodegenerative diseases like Alzheimer's. The compound works independently of cannabinoid receptors, making it a promising therapeutic option.
Researchers identified gaps in care and treatment for women with Parkinson's Disease, highlighting the need for personalized medicine and psychosocial support. The study calls for increased attention to sex and gender differences in PD management.
During the first wave of the COVID-19 pandemic in Canada, researchers found increased health service use and higher death rates among adults with dementia and Parkinson disease. The study examined changes in these populations compared to older adults without neurodegenerative diseases.
Regular aerobic exercise has been shown to strengthen brain networks between spared regions, improve grey-matter volume, and enhance movement control in individuals with Parkinson's disease. The study published in Annals of Neurology suggests that exercise can stimulate compensatory capacity in the brain, leading to reduced symptoms.
UC researchers received a $1.2 million grant to examine the impact of stress hormone receptors on cell degeneration in Parkinson's disease. The study aims to develop a new model that better replicates the progression of the disease, which may lead to treatments targeting stress hormone blockers or next-generation therapeutics.
A new study suggests that regular exercise can slow the progression of Parkinson's disease in people with early-stage symptoms. Those who engaged in moderate exercise for at least four hours a week experienced less trouble balancing, walking, and performing daily activities over time.
Researchers at the University of Bergen have discovered a new understanding of dopamine's regulatory mechanisms, which could lead to breakthroughs in treating neurodegenerative diseases. The study found that dopamine can bind to an enzyme called tyrosine hydroxylase, inactivating it and controlling its own production.
Researchers at Waseda University discovered a new protein isoform called Senp5S, which helps regulate Drp1 and mitochondrial dynamics during brain development. The study suggests a novel and vital role for post-translational SUMOylation in neuronal differentiation.
A new study led by Mount Sinai researchers found that microglia may play a critical role in some cases of brain disease, and provides a comprehensive guide for future studies. The study identified two new genes linked to brain disorders, including Alzheimer's and Parkinson's diseases.
Researchers have solved a decade-long mystery about the PINK1 protein, which plays a critical role in early onset Parkinson's disease. The discovery provides an unprecedented view of the protein and its activation process, paving the way for developing therapeutic agents that could slow or stop the progression of Parkinson's disease.
Researchers at Bar-Ilan University used a crowd-sourced approach to test the effectiveness of mannitol in treating Parkinson's disease. The study, published in BioSocieties, chronicles the story of CliniCrowd, an Israeli company that recruited patients and collected data on mannitol's effects.
Researchers found that a Parkinson's disease mutation mislocalizes iron in activated microglia, leading to toxic iron accumulation. This mislocalization may explain the disease's progression and provide a basis for therapies targeting LRRK2.
Researchers found that the SARS-CoV-2 N-protein accelerates the formation of amyloid fibrils in test tube experiments, interacting with α-synuclein protein. This interaction may contribute to the development of Parkinson's disease in COVID-19 patients.
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
Researchers have determined the molecular structure of TDP-43 aggregates extracted from human brains, shedding light on its role in neurodegenerative diseases like ALS. The discovery may lead to the development of targeted therapies and diagnostic tests.
A new study has identified a promising drug candidate to minimize uncontrolled muscle movements associated with Parkinson’s disease. PD13R reduced dyskinesia by more than 85% in animal studies, also improving sleep quality compared to other treatments.
Young veterans with mTBI experience premature cognitive decline in specific domains, matching elder normative scores and early-stage Parkinson's patients. The study highlights the significant negative impact of mTBI on cognitive function compared to healthy non-veterans.
The American Academy of Neurology has issued a guideline recommending treatment options for early Parkinson's disease, including levodopa as the best first treatment. The guideline also highlights potential side effects and risks associated with medications, such as dyskinesia and impulse-control disorders.
Researchers identified a significant vascular defect in patients with moderately severe Parkinson's disease, which may explain earlier study findings and provide a new target for therapeutic intervention. The discovery highlights the blood-brain barrier's crucial role in neurodegenerative diseases like Parkinson's.
Researchers at Newcastle University have found that increased levels of ceramides and alpha-synuclein protein in extracellular vesicles could help diagnose Lewy body dementia and test treatment effectiveness. The findings may lead to a more accurate diagnosis for the over 100,000 people affected by the disease.
Researchers have made significant breakthroughs in understanding Parkinson's disease, revealing that affected neurons don't die but lose properties. This knowledge opens the door to new therapeutic treatments targeting the cell body, rather than just axons.
Researchers have demonstrated the effectiveness of polymer-coated nanoparticles in delivering drugs to the brain, overcoming the blood-brain barrier challenge. The study showed that zwitterionic polymers improve accessibility but are rapidly absorbed by blood vessel walls.
Researchers will investigate brain circuits involved in the placebo effect and paradoxical kinesia, a phenomenon where Parkinson's patients exhibit normal motor function under specific circumstances. The study aims to identify new locations for deep brain stimulation placement and discover new treatments for Parkinson's disease.
Researchers developed a new NMR spectroscopic method to map IDP function more easily, fast, and accurately. The method sheds light on mechanisms of diseases like Parkinson's, Alzheimer's, and type 2 diabetes.
Researchers have made significant progress in generating neurons in the lab, a potential therapeutic option for replacing lost neurons in neurodegenerative conditions like Parkinson's disease. A $9 million grant will support further research and development of this novel treatment approach.
A new study found a significant increase in US Parkinson's disease deaths over the past two decades, with mortality rates twice as high in men as in women. White people were also more likely to die from the disease, potentially due to socioeconomic factors affecting access to healthcare.
A rhythmic approach to music therapy is being tested to improve fine motor skills in Parkinson's patients. The therapy uses specific combinations of rhythm and movement to reprogram brain frequencies, with promising results so far.
A preclinical study found that blocking the Bach1 protein slowed brain cell deterioration in Parkinson's disease. The researchers identified a potent inhibitor of Bach1 called HPPE, which protected cells from inflammation and oxidative stress, and showed promise as a potential therapeutic target.
Researchers at Duke University used new tools to monitor neurons and analyze machine learning data to see how zebra finches practice their courtship calls. They found that a neurotransmitter called noradrenaline shuts down variability in the song, making it more precise when performed under pressure.
Scientists at the University of Groningen developed wearable, stitchable, and sensitive sensors from flexible polymers and carbon fibre. These sensors can measure body position, movement, and touch, offering new possibilities for health monitoring and athlete performance tracking.
Michel Goedert's research focuses on protein aggregates in Alzheimer's and Parkinson's, providing deep insights into disease development. His work is essential for finding new treatments, as evidenced by his discovery of gene mutations leading to dementia.
A study published in Aging-US reveals that protein processing impairment in Parkinson's disease is mediated by chromogranin/secretogranin, leading to decreased candidate proteins and peptides. This finding suggests a potential therapeutic target for the treatment of PD.
A recent study suggests that targeting alpha-synuclein protein in Parkinson's disease may not be sufficient to cure most patients. Instead, resolving brain inflammation caused by dysfunctional interferon-beta receptor signaling may hold the key to developing more effective treatments.
Researchers at Carnegie Mellon University have found a way to make deep brain stimulation (DBS) more precise, resulting in therapeutic effects that outlast what is currently available. The new protocol uses short bursts of electrical stimulation to target specific neuronal subpopulations, providing longer-lasting benefits.
Scientists have developed an improved technique to trace brain connections between neurons in zebrafish using vesicular stomatitis virus (VSV), enabling the visualization of connected neurons up to five days after infection. This breakthrough could provide insights into brain network connectivity repair after injury or disease.
A new study found that toxic fatty acids produced by astrocytes can trigger cell death in damaged neurons, which may contribute to neurodegenerative diseases such as glaucoma and Alzheimer's. Blocking the production of these fatty acids in mice preserved 75% of neurons, suggesting a promising target for treatment.
Researchers will investigate hidden signs of brain damage in REM behavior disorder, aiming to identify biomarkers that predict impending neurological disease. The goal is to delay the onset or prevent dementia or Parkinsonism through clinical trials.
The Michael J. Fox Foundation has defined four major areas of action to reduce health disparities and advance treatments for everyone with PD. The foundation is launching a new funding opportunity to study incidence, etiology, and pathology in underrepresented populations.
Researchers highlight current strategies to restore lost function and replace what is lost in the PD brain, including cell and gene therapy approaches. Pioneering trials face regulatory and ethical challenges that require incremental development and step-wise optimization of products.
Researchers have identified a molecule that slows cells' production of alpha-synuclein, a protein forming toxic aggregates in Parkinson's brains. The compound, A-443654, also reduces cell stress and may help degrade existing alpha-synuclein aggregates.
Researchers at The Graduate Center, CUNY, found that increased signaling of the sonic hedgehog protein can inhibit LID in animal models of Parkinson's disease. This could lead to a potential therapeutic solution for most Parkinson's patients.
Researchers at Rush University Medical Center have developed potential new treatments for Parkinson’s disease that showed success in slowing its progression in mice. The lab-developed peptides helped slow the spread of alpha-synuclein, a protein that occurs in abnormal deposits in the brain.
The USC Institute is launching a $3 million global consortium study to analyze brain imaging, genetics, and clinical data from 20 countries. The study aims to understand how Parkinson's disease progresses in the brain and explore genetic factors contributing to risk.
Researchers at the University of Helsinki have identified two distinct patterns of alpha-synuclein accumulations in the olfactory bulb, associated with differing disease types of dementia with Lewy bodies. These findings support the classification of the disease into two distinct forms, one progressing to the amygdala and another to th...
Researchers surveyed 4,324 people with Parkinson's and found that many are unaware of all seven compensation strategies, but most who tried them reported positive effects. The study suggests a 'one-size-fits-all' approach doesn't work, emphasizing the need for personalized education on available strategies.
Researchers created tiny human midbrain-like organoids that mimic the major pathological features of Parkinson's disease. These organoids enable scientists to study how the human brain develops and communicates, providing insights into the progression of the disease and potential new treatments.
Researchers developed a new AI algorithm called 'basis profile curve identification' to simplify comparisons between effects of electrical stimulation on the brain. The algorithm may help understand which brain regions interact with each other, guiding placement of electrodes for treating network brain diseases.
A new unsupervised machine learning algorithm, B-SOiD, developed by Carnegie Mellon University researchers makes studying animal behavior more accurate and efficient. The algorithm identifies patterns in an animal's body position to discover behaviors, removing human error and bias.
A new European survey sheds light on the lives of people with Parkinson's disease and their carers, revealing a wide range of non-motor symptoms affecting quality of life. The study highlights the importance of individualized management and improved clinical practice in addressing the unique challenges faced by patients and caregivers.
A new study found that patients with advanced Parkinson's disease are at higher risk of contracting and suffering from respiratory illnesses like influenza and pneumonia. Neurologists are advised to actively encourage vaccinations for these patients, particularly in the light of COVID-19.
Researchers discovered that a brain area traditionally thought to specialize in old habits also plays a role in learning new actions. The study found that the dorsolateral striatum is involved in consolidating action learning immediately after the new action has been learned.
Researchers identified physical binding sites for cholesterol in GIRK channels, which play a role in neurodegenerative diseases. The study provides structural insights into how cholesterol alters channel function, paving the way for drug development.
A study found that transcranial stimulation can increase the benefits of aerobic exercise and improve gait in Parkinson's patients. The treatment uses a weak current delivered by electrodes placed over specific brain regions, activating the pre-frontal cortex.
A new UBCO study determines that wearable technology and telehealth can tailor treatment plans for Parkinson's disease by identifying peak times of symptoms. The research found positive experiences and health outcomes for patients using wearable devices in combination with telehealth appointments.
Impaired information flow through the basal ganglia is responsible for Parkinson's disease symptoms. The 'direct pathway' plays a crucial role in initiating voluntary movements, and its disturbance leads to motor symptoms like trembling hands and muscle stiffness.
Researchers at Niigata University have identified a key pathway involving the protein optineurin that may contribute to the development of amyotrophic lateral sclerosis (ALS) disease. The study found that optineurin inhibits the formation of stress-induced TDP-43 protein aggregates in motor neurons, which are a hallmark of ALS.
Researchers at Oregon Health & Science University have successfully used a synthetic compound to regulate the TREM2 gene, implicated in neurodegenerative diseases. The findings raise hope for developing new treatments for Alzheimer’s and Parkinson’s.
Scientists discovered a new mitochondrial recycling pathway that may help prevent Parkinson's disease. The study, published in Science Advances, reveals that genes associated with Parkinson's disease play key roles in this process and that disruptions can contribute to neurodegeneration.
A study in mice shows that an experimental small molecule helped restore the removal of damaged mitochondria from dopamine-producing brain cells, which may help explain what goes wrong in people with mutations that cause Parkinson's disease. The findings highlight the potential benefit of LRRK2 inhibitors as treatments for the disease.